In Reply to Dr. Lee

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 5, 2009, Pages 1332-1333

  Fowler, Jack F ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; DOSE RESPONSE; HUMAN; LETTER; MEDICAL DECISION MAKING; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR RECURRENCE;

DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RISK; TREATMENT FAILURE;

EID: 67651120165     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.065     Document Type: Letter

References (14)

1. Fowler JF. Comments on "Magical Protons?" [Letters to the Editor]. Int J Radiat Oncol Biol Phys 2008;70:654-656. Int J Radiat Oncol Biol Phys 2008;72:1270-1271.
2. Withers HR, Peters LJ. Comments on "Magical Protons." Int J Radiat Oncol Biol Phys 2008;70:654-656; In reply to Dr. Fowler [Letters to the Editor]. Int J Radiat Oncol Biol Phys 2008;72:1271.
3. Lee W.R. The ethics of hypofractionation for prostate cancer [Letters to the Editor]. Int J Radiat Oncol Biol Phys 73 (2009) 969-970
4. Hoskins P.J., and Dearnaley D.P. Hypofractionation in clinical trials for prostate cancer [editorial]. Clin Oncol 19 (2007) 287-288
5. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1111
6. Dasu A. Is the α/β value for prostate tumors low enough to be safely used in clinical trials?. Clin Oncol 19 (2007) 289-301
7. Bentzen S.M., and Ritter M.A. The α/β ratio for prostate cancer: What is it, really? [editorial]. Radiother Oncol 76 (2005) 1-3
8. Williams S.G., Taylor J.M.G., Liu H., et al. Use of individual fraction size data from 3756 patients to directly determine the α/β ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 23-33
9. Miralbell R, Roberts SA, Zubizaretta E, Hendry JH. Dose-fraction sensitivities of low/middle/high risk prostate cancer deduced from seven international primary institutional datasets. Proceedings of the 2009 Annual meeting of the UK Association of Radiation Research, Glasgow, June 22nd-24th, (47th year)
10. Huang E.H., Pollock A., Levy L., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1314-1321
11. Brenner D.J. Fractionation and late rectal toxicity. [editorial]. Int J Radiat Oncol Biol Phys 60 (2004) 1013-1015
12. Fowler J.F., Harari P.M., Leborgne F., and Leborgne J.H. Acute radiation reactions in oral and pharyngeal mucosa: Tolerable levels in altered fractionation schedules. Radiother Oncol 69 (2003) 161-168
13. Leborgne F., and Fowler J.F. Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionayion. Int J Radiat Oncol Biol Phys 72 (2008) 770-776
14. Coote J.H., Wylie J.P., Cowan R.A., et al. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys (2009) Electronic prepublication Jan 7th